What is Alpine Immune Sciences Financial Strength?
Alpine Immune Sciences has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Alpine Immune Sciences Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate Alpine Immune Sciences's interest coverage with the available data.
Alpine Immune Sciences's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.34.
As of today, Alpine Immune Sciences's Altman Z-Score is 65.00.
Competitive Comparison of Alpine Immune Sciences's Financial Strength
For the Biotechnology subindustry, Alpine Immune Sciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpine Immune Sciences's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's Financial Strength distribution charts can be found below:
* The bar in red indicates where Alpine Immune Sciences's Financial Strength falls into.
Alpine Immune Sciences Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Alpine Immune Sciences's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-22.70 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $8.71 Mil.
Alpine Immune Sciences's Interest Coverage for the quarter that ended in Mar. 2024 is
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Alpine Immune Sciences's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Alpine Immune Sciences has a Z-score of 65.00, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 65 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpine Immune Sciences (Alpine Immune Sciences) Business Description
Traded in Other Exchanges
Address
188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Executives
| Mitchell Gold |
director, officer: Executive Chairman and CEO |
ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102 |
| Peter A. Thompson |
director |
C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
| Orbimed Advisors Llc |
director |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| James Paul Rickey |
officer: Senior VP and CFO |
ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102 |
| Xiangmin Cui |
director, 10 percent owner |
NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000 |
| Wolfgang Dummer |
officer: Chief Medical Officer |
5491 OPTICAL CT., SAN JOSE CA 95138 |
| Remy Durand |
officer: Chief Business Officer |
C/O ALPINE IMMUNE SCIENCES, INC., 185 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98012 |
| Jorn Drappa |
director |
C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878 |
| Andrew Seth Sandler |
officer: Chief Medical Officer |
1301 2ND AVE, SEATTLE WA 98101 |
| Frazier Life Sciences Viii, L.p. |
10 percent owner |
601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
| Robert E Conway |
director |
C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021 |
| Christopher Peetz |
director |
C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080 |
| Decheng Capital China Life Sciences Usd Fund Iii, L.p. |
10 percent owner |
UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104 |
| Alpine Immunosciences, L.p. |
10 percent owner |
600 STEWART STREET, SUITE 1503, SEATTLE WA 98101 |
| Orbimed Genesis Gp Llc |
director, 10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Alpine Immune Sciences (Alpine Immune Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALPN has been successfully added to your